NovoPedics

NovoPedics, Inc. is a medical technology company specializing in innovative solutions for orthopedic surgery, focusing on total meniscus replacement technologies. NovoPedics, Inc. develops advanced medical devices for orthopedic applications, specifically targeting knee surgeries.

Founded by Charles Gatt and Michael Dunn, the company is headquartered in New Brunswick, US. In April 2013, NovoPedics raised USD 500,000 from Foundation Venture Capital Group, marking its only known funding round to date. NovoPedics, Inc. specializes in the development of MeniscoFix™, a polymer fiber-reinforced scaffold designed for total meniscus replacement in the knee.

This medical device is intended for gradual absorption by the body, replaced with new tissue, mimicking the natural meniscus. MeniscoFix™ is implanted through arthroscopically-assisted surgery, allowing for minimally invasive procedures beneficial for patients with significant meniscal damage. The primary end users include orthopedic surgeons and healthcare providers involved in knee surgeries, with the company targeting markets in the United States and seeking expansion into European and Asian markets where orthopedic procedures are common. NovoPedics generates revenue through the sale of MeniscoFix™, marketed to hospitals and surgical centers specializing in orthopedic procedures.

The revenue model emphasizes direct sales to healthcare providers, with potential partnerships for broader distribution. Healthcare facilities may procure MeniscoFix™ through bulk orders or purchasing agreements for consistent supply. Although specific pricing details are not disclosed, the pricing strategy reflects the advanced technology and biocompatible materials used in MeniscoFix™, positioning it as a premium solution in the orthopedic market. Recent achievements include receiving a NIH SBIR grant and Breakthrough Device Designation from the FDA, which may positively influence revenue streams through increased adoption by medical professionals.

NovoPedics is focused on expanding its product line and market reach. The company aims to enhance its offerings with new products designed for orthopedic applications, although specific upcoming products and release dates are not disclosed. It plans to enter European and Asian markets, targeting expansion within the next few years. The capital raised in April 2013 will support these initiatives, providing resources for product development and market entry strategies.